Clearside Biomedical, Inc. to Present at J.P. Morg
Post# of 301275
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that Daniel H. White, Chief Executive Officer and President of Clearside, will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2017 at 7:30am PST, at the Westin St. Francis Hotel, in San Francisco, California.
The presentation will be webcast live and may be accessed by visiting Clearside’s website at http://ir.clearsidebio.com . A replay of the webcast will be available for 30 business days.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly traded, ophthalmic biopharmaceutical company that envisions a world without blindness. Clearside relentlessly pursues transformative, elegant, precise solutions to restore and preserve vision. Clearside is developing advanced clinical and pre-clinical candidates using a proprietary treatment approach offering unprecedented access to the back of the eye through the suprachoroidal space (SCS™). This offers potentially meaningful treatment benefit to patients suffering from sight threatening diseases like uveitis, retinal vein occlusion, diabetic macular edema and wet age-related macular degeneration. To learn more about how Clearside is changing ophthalmology, please visit us at www.clearsidebio.com .
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 charlie.deignan@clearsidebio.com Investors: Matthew Beck The Trout Group 646-378-2933 mbeck@troutgroup.com
(0)
(0)